Mediolanum International Funds Ltd Has $8.58 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Mediolanum International Funds Ltd boosted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 18.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 127,725 shares of the medical device company's stock after buying an additional 20,337 shares during the period. Mediolanum International Funds Ltd's holdings in DexCom were worth $8,580,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Crewe Advisors LLC bought a new stake in DexCom during the 1st quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom in the second quarter worth $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after purchasing an additional 171 shares during the last quarter. DT Investment Partners LLC grew its position in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new stake in DexCom in the 1st quarter valued at $55,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent research reports. Baird R W downgraded DexCom from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 26th. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday. Barclays dropped their price target on shares of DexCom from $138.00 to $113.00 and set an "equal weight" rating on the stock in a research report on Monday, July 29th. StockNews.com raised shares of DexCom from a "hold" rating to a "buy" rating in a research report on Friday. Finally, BTIG Research cut their target price on shares of DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Price Performance

DexCom stock traded down $1.41 during trading hours on Friday, reaching $73.44. 14,562,597 shares of the stock were exchanged, compared to its average volume of 3,904,948. The stock has a 50 day moving average of $70.11 and a two-hundred day moving average of $98.24. The company has a market cap of $29.21 billion, a P/E ratio of 47.38, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $994.20 million for the quarter, compared to analysts' expectations of $991.55 million. Equities analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 652 shares of the firm's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company's stock, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock worth $126,390 in the last ninety days. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.